Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Looks To The New As It Braces For Velcade Generics

Executive Summary

Takeda is facing major revenue challenges from US generics to its big seller Velcade, but is looking to successor and other new products to more than plug the gap.

You may also be interested in...



Takeda Bumps Forecast On 'Significant Momentum' Pre-Shire

Takeda raises full-year forecast after "significant momentum" in the first half, driven by mainstays, cost savings and delayed US generic competition to Velcade.

Shire Integration Prep Progresses As Takeda Logs Solid 1Q

Takeda and Shire are already discussing their planned integration across multiple areas, but until the deal closes formally the Japanese firm stresses it is business as usual, as it reports solid underlying growth in the fiscal first quarter, driven by core products.

Sub Q Maintenance Success Set To Improve Entyvio's Position In Ulcerative Colitis

New positive data with more convenient formulation set stage for increased Entyvio competitiveness in ulcerative colitis maintenance setting, while other early results bode well for Ninlaro in maintenance use in multiple myeloma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel